Lentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 27 (9), 459-469
- https://doi.org/10.1038/s41434-020-0164-6
Abstract
Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disorder characterised by recurrent and often life-threatening infections and hyperinflammation. It is caused by defects of the phagocytic NADPH oxidase, a multicomponent enzyme system responsible for effective pathogen killing. A phase I/II clinical trial of lentiviral gene therapy is underway for the most common form of CGD, X-linked, caused by mutations in the gp91phox subunit of the NADPH oxidase. We propose to use a similar strategy to tackle p47phox-deficient CGD, caused by mutations in NCF1, which encodes the p47phox cytosolic component of the enzymatic complex. We generated a pCCLCHIM-p47phox lentiviral vector, containing the chimeric Cathepsin G/FES myeloid promoter and a codon-optimised version of the human NCF1 cDNA. Here we show that transduction with the pCCLCHIM-p47phox vector efficiently restores p47phox expression and biochemical NADPH oxidase function in p47phox-deficient human and murine cells. We also tested the ability of our gene therapy approach to control infection by challenging p47phox-null mice with Salmonella Typhimurium, a leading cause of sepsis in CGD patients, and found that mice reconstituted with lentivirus-transduced hematopoietic stem cells had a reduced bacterial load compared with untreated mice. Overall, our results potentially support the clinical development of a gene therapy approach using the pCCLCHIM-p47phox vector.Keywords
Funding Information
- Action Medical Research
This publication has 33 references indexed in Scilit:
- NADPH Oxidase Deficient Mice Develop Colitis and Bacteremia upon Infection with Normally Avirulent, TTSS-1- and TTSS-2-Deficient Salmonella TyphimuriumPLOS ONE, 2013
- Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 proteinNature, 2011
- Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid CellsMolecular Therapy, 2011
- Gene Therapy of Chronic Granulomatous Disease: The Engraftment DilemmaMolecular Therapy, 2011
- Residual NADPH Oxidase and Survival in Chronic Granulomatous DiseaseNew England Journal of Medicine, 2010
- Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous diseaseNature Medicine, 2010
- Chronic Granulomatous Disease: The European ExperiencePLOS ONE, 2009
- Novel cell death program leads to neutrophil extracellular trapsThe Journal of cell biology, 2007
- Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1Nature Medicine, 2006
- With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIVMACGene Therapy, 2006